Trial Profile
A Multicentre, Open Label, Follow on Study to Assess the Maintenance of Effect, Tolerance and Safety of Sativex in the Treatment of Subjects With Neuropathic Pain. This Will be Followed by a Randomised-Withdrawal Phase (Part B) for a Subset of Patients.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Nabiximols (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions; Therapeutic Use
- Sponsors GW Pharmaceuticals
- 16 Aug 2012 Primary endpoint amended as reported by ClinicalTrials.gov. (NCT00713323)
- 16 Aug 2012 Primary endpoint amended as reported by ClinicalTrials.gov. (NCT00713323)
- 06 Sep 2006 New trial record.